XBiotech Inc. (XBIT) annual cash flow statement — 14-year operating, investing & financing history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 |
|---|
| Cash from Operations | -42.17M | -39.92M | -30.96M | -18.73M | -14.82M | 69.44M | -65.15M | -18.27M | -16.54M | -33.65M | -46.02M | -33.31M | -11.7M | -8.91M | -11.63M |
| Operating CF Margin % | - | - | - | - | -369.68% | 377.54% | -148.08% | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -209.93% | -28.93% | -65.36% | -26.32% | -121.35% | 206.59% | -256.59% | -10.48% | 50.85% | 26.87% | -38.15% | -184.68% | -31.34% | 23.43% | - |
| Net Income | -40.16M | -45.54M | -38.53M | -24.56M | -32.9M | -17.41M | -11.22M | 668.63M | -21.14M | -33.15M | -52.76M | -37.48M | -21.72M | -9.93M | -15.16M |
| Depreciation & Amortization | 1.58M | 1.69M | 1.75M | 1.74M | 2.61M | 2.65M | 2.24M | 2.36M | 2.43M | 1.48M | 698K | 699K | 664K | 784K | 946K |
| Stock-Based Compensation | 131K | 3.62M | 1.75M | 3.26M | 5.06M | 4.46M | 12.58M | 3.36M | 1.66M | 1.75M | 5.57M | 4.41M | 7.02M | 739K | 2.82M |
| Deferred Taxes | 5K | 5K | 0 | 0 | 0 | 0 | -90K | -444K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.58M | -3.33M | 5.53M | -1.89M | 2.8M | 0 | 90K | -674.56M | 6.53M | 401K | 6.97M | -157K | 1.07M | 103K | 2.58M |
| Working Capital Changes | -2.14M | 3.64M | -1.46M | 2.72M | 7.6M | 79.75M | -68.75M | -17.62M | 508K | -4.13M | 475K | -774K | 2.34M | -504K | -236K |
| Change in Receivables | 412K | 574K | 77K | 829K | 7.34M | 1.73M | -10.69M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -241K | -688K | -364K | 91K | 357K | -514K | -334K | 496K | -78K | -2.7M | -981K | 840K | 1.07M | 103K | -199K |
| Cash from Investing | -186K | -289K | -1.3M | 61.5M | -63.89M | -3.52M | -3.73M | 674.8M | -122K | -1.41M | -13.91M | -10.39M | -1.4M | -59K | -550K |
| Capital Expenditures | -195K | -289K | -1.3M | -362K | -585K | -3.52M | -3.73M | -204K | -122K | -1.41M | -13.91M | -10.39M | -1.4M | -59K | -550K |
| CapEx % of Revenue | - | - | - | - | 14.59% | 19.16% | 8.47% | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 675M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 9K | 0 | 0 | 61.86M | 0 | 0 | 0 | 0 | 0 | 0 | -9.17M | -8.07M | 0 | 0 | 0 |
| Cash from Financing | 0 | -10.25M | 10.45M | -9K | 0 | -67.01M | -409.72M | 42.1M | 201K | 33.32M | 2.94M | 77.47M | 63.2M | 12.04M | 7.28M |
| Debt Issued (Net) | 0 | -10.25M | 10.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 5K | 0 | 0 | -420M | 38.06M | 0 | 32.62M | 1.81M | 75.71M | 63.37M | 12.04M | 7.15M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | -75M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -420M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 200K | -14K | 0 | 8M | 10.28M | 4.03M | 201K | 703K | 1.14M | 1.76M | -174K | 0 | 135K |
| Net Change in Cash | -40.44M | -47.13M | -27.35M | 42.72M | -79.68M | -383K | -477.23M | 698.77M | -15.95M | -2.56M | -56.73M | 33.72M | 50.09M | 3.08M | -4.9M |
| Free Cash Flow | -42.36M | -40.21M | -32.27M | -19.09M | -15.41M | 65.92M | -68.88M | -18.47M | -16.66M | -35.05M | -59.93M | -43.7M | -13.1M | -8.97M | -12.18M |
| FCF Margin % | - | - | - | - | -384.26% | 358.38% | -156.55% | - | - | - | - | - | - | - | - |
| FCF Growth % | -33.96% | -24.61% | -69.05% | -23.87% | -123.38% | 195.71% | -272.83% | -10.9% | 52.48% | 41.51% | -37.14% | -233.66% | -46.06% | 26.4% | - |
| FCF per Share | -1.39 | -1.32 | -1.06 | -0.63 | -0.51 | 2.19 | -2.23 | -0.40 | -0.47 | -1.01 | -1.85 | -1.42 | -0.41 | -0.28 | -0.38 |
| FCF Conversion (FCF/Net Income) | 1.05x | 0.88x | 0.80x | 0.76x | 0.45x | -3.99x | 5.81x | -0.03x | 0.78x | 1.02x | 0.87x | 0.89x | 0.54x | 0.90x | 0.77x |
| Interest Paid | 0 | 0 | 400K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 85K | 0 | 0 | 0 | 54.09M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying XBIT stock.
XBiotech Inc. (XBIT) generated $-39.9M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
XBiotech Inc. (XBIT) reported negative free cash flow of $40.2M in 2025, indicating capital requirements exceeded cash from operations.
XBiotech Inc. (XBIT) spent $0.3M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.